Apollomics (NASDAQ:APLM) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Apollomics (NASDAQ:APLM) to a hold rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings raised shares of Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Apollomics Stock Performance

NASDAQ:APLM opened at $24.33 on Friday. Apollomics has a fifty-two week low of $3.66 and a fifty-two week high of $42.12. The company’s 50-day simple moving average is $19.03 and its 200-day simple moving average is $17.47.

Insider Buying and Selling at Apollomics

In other Apollomics news, CFO Peter Kuan-How Lin purchased 26,667 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $400,005.00. Following the completion of the purchase, the chief financial officer owned 48,979 shares of the company’s stock, valued at approximately $734,685. The trade was a 119.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Yi-Kuei Chen acquired 20,000 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were bought at an average price of $15.00 per share, for a total transaction of $300,000.00. Following the acquisition, the chief operating officer owned 121,248 shares of the company’s stock, valued at approximately $1,818,720. This represents a 19.75% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 583,334 shares of company stock worth $8,250,510.

Institutional Trading of Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC bought a new position in shares of Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics at the end of the most recent quarter. 19.13% of the stock is owned by institutional investors.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.